Treatment of resistance to tremelimumab

Tremelimumabis a cytotoxicT lymphocyte-associated antigen 4 (CTLA-4) blocking human IgG2 monoclonal antibody, produced in NS0 cell suspension culture through recombinant DNA technology, with a molecular weight of 149kD, and the monoclonal antibody bindsCT LA-4 also blocks the interaction with its ligands CD80 and CD86, releasing CTLA-4-mediated inhibition of T cell activation. It will reach a stable state after 12 weeks of use.

There are many clinical trials investigating the efficacy of temsitumumab, and some studies have shown that temsitumumab may produce durable therapeutic responses and extend survival in a subset of patients, including adult patients with unresectable hepatocellular carcinoma (uHCC) and metastatic non-small cell lung cancer (NSCLC) without sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor abnormalities. . However, for other patients, the effects of temsitumumab may be less pronounced or temporary. Temtumumab is an emerging treatment method. Compared with chemotherapy alone, the combination of imrvalumab and chemotherapy can prolong the patient's life. Everyone's physique is different and their resistance to drugs is also different. If you feel unwell, please inform your doctor in time.

Tesetumumab is an emerging cancer immunotherapy drug that has not yet been launched in China, so it has not been included in the medical insurance. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab’s original drug has been on the market overseas for a short time, and the price is not yet clear. There is currently no known generic version of temsitumumab that has been produced and launched. For specific prices and drug details, please consult Yaode’s medical consultant.